Quantitative Prognostic Prediction Using ADV Score for Hepatocellular Carcinoma Following Living Donor Liver Transplantation

Hwang, Shin; Song, Gi‐Won; Ahn, Curie; Kim, Ki‐Hun; Moon, Deok‐Bog; Ha, Tae‐Yong; Jung, Dong‐Hwan; Park, Gil‐Chun; Yoon, Young‐In

doi:10.1007/s11605-021-04939-w

Cited by 15 publications

(52 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Complete tumor necrosis is defined as the absence of viable HCC in the explanted liver; however, risk of HCC recurrence still exists because it appears to be a downstaging of the disease. An ADV score of 0 can theoretically be obtained in patients showing complete tumor necrosis, in which the prognosis of these patients was quite comparable to that of patients with ADV scores <2 log [20].…”

Section: Prognostic Impact Of Pretransplant Treatment-induced Complete Tumor Necrosis From Asan Medical Center (2017) [25]mentioning

confidence: 87%

“…In contrast, the Kyoto criteria include tumor size, number and PIVKA-II, but the AFP level is omitted [31]. Because the measurement of both AFP and PIVKA-II has been routinely performed in Korea, the selection criteria developed in Korea usually include these two tumor markers at to enhance the predictive power [12,15,16,20]. A retrospective data analysis of the Japanese nationwide survey established new expanded criteria for LDLT candidates with HCC, the 5-5-500 rule (nodule size ≤5 cm in diameter, nodule number ≤5, and AFP value ≤500 ng/mL), which showed a 5-year tumor recurrence rate of 7.3% [32].…”

Section: Discussionmentioning

confidence: 99%

“…Quantitative Prognostic Prediction Using AFP-PIVKA-II-Tumor Volume (ADV) Score in Asan Medical Center (2021) [20] The authors assessed the prognostic impact of AFP-des-γ-carboxyprothrombin [DCP or PIVKA-II]-tumor volume (ADV) score for predicting HCC recurrence and OS after LDLT. This study included 843 patients who underwent LDLT for HCC between 2006 and 2015.…”

Section: Composite Criteria Using Clinical and Fdg Pet Factors In Seoul National University Hospital And Samsung Medical Center (2019) [1mentioning

confidence: 99%

“…In contrast, the ADV score is an integrated surrogate marker enabling the reliable prediction of posttransplant prognosis in a quantitative manner. Currently, there are only two selection criteria enabling quantitative prognostic prediction, Metroticket 2.0 criteria [21] and ADV score [20]. The posttransplant prognosis of HCC patients according to the Metroticket 2.0 criteria (tumor diameter+number) ≤7 & AFP ≤200/400/1,000 ng/ mL is comparable to that of ADV score <5 log [20].…”

Section: Composite Criteria Using Clinical and Fdg Pet Factors In Seoul National University Hospital And Samsung Medical Center (2019) [1mentioning

confidence: 99%

“…Currently, there are only two selection criteria enabling quantitative prognostic prediction, Metroticket 2.0 criteria [21] and ADV score [20]. The posttransplant prognosis of HCC patients according to the Metroticket 2.0 criteria (tumor diameter+number) ≤7 & AFP ≤200/400/1,000 ng/ mL is comparable to that of ADV score <5 log [20]. The ADV score appears to be intuitive in assessing prognosis because there is only one continuous value.…”

Section: Composite Criteria Using Clinical and Fdg Pet Factors In Seoul National University Hospital And Samsung Medical Center (2019) [1mentioning

confidence: 99%

See 4 more Smart Citations

Selection criteria of living donor liver transplantation for hepatocellular carcinoma developed in Korean transplant centers

Jung

Hwang

Song

2021

Ann Liver Transplant

Self Cite

View full text Add to dashboard Cite

With accumulated experience on living donor liver transplantation (LDLT) for hepatocellular carcinoma (HCC), several major Korean transplant centers presented institutional or multicenter selection criteria of LDLT for HCC based on their own experience. This study intended to review the selection criteria of LDLT for HCC developed in the major Korean LT centers. Extended criteria for primary liver transplantation (LT) were developed in Asan Medical Center (AMC) in 2008, the Catholic University of Korea in 2012, Samsung Medical Center in 2014, National Cancer Center Korea in 2016, the model to predict tumor recurrence after LDLT (MoRAL) in three centers in 2016, A-P 200 criteria in Pusan National University in 2016, patient selection by tumor markers in LT for advanced HCC in eight centers, composite criteria using clinical and PET factors in two centers in 2019, tumor size and number, AFP, PIVKA-II, PET (SNAPP) score in AMC in 2021, and quantitative prognostic prediction using AFP-PIVKA-II-tumor volume (ADV) score in AMC in 2021. The criteria for salvage LT were developed from a multicenter study involving three centers in 2014 and from AMC in 2020. Posttransplant prognostic prediction models for early or non-viable HCC were developed in AMC for super-selection criteria in 2011 and pretransplant treatment-induced complete tumor necrosis in 2017. The importance of tumor biology in HCC treatment has been emphasized more than before. The expression of serum tumor markers is a surrogate biomarker reflecting the tumor biology. Pretransplant radiological assessment of HCC combined with tumor marker expression or PET finding will provide reliable information that will assist the decision to perform LDLT in patients with HCC of various stages.

show abstract

Section: Prognostic Impact Of Pretransplant Treatment-induced Complete Tumor Necrosis From Asan Medical Center (2017) [25]mentioning

confidence: 87%

Section: Discussionmentioning

confidence: 99%

Section: Composite Criteria Using Clinical and Fdg Pet Factors In Seoul National University Hospital And Samsung Medical Center (2019) [1mentioning

confidence: 99%

Section: Composite Criteria Using Clinical and Fdg Pet Factors In Seoul National University Hospital And Samsung Medical Center (2019) [1mentioning

confidence: 99%

Section: Composite Criteria Using Clinical and Fdg Pet Factors In Seoul National University Hospital And Samsung Medical Center (2019) [1mentioning

confidence: 99%

See 3 more Smart Citations

Selection criteria of living donor liver transplantation for hepatocellular carcinoma developed in Korean transplant centers

Jung

Hwang

Song

2021

Ann Liver Transplant

Self Cite

View full text Add to dashboard Cite

show abstract

Validation of quantitative prognostic prediction using ADV score for resection of hepatocellular carcinoma: A Korea–Japan collaborative study with 9200 patients

Kang

Hwang

Kaibori

et al. 2023

J Hepato Biliary Pancreat

Self Cite

View full text Add to dashboard Cite

BackgroundA score derived from the concentrations of α‐fetoprotein (AFP) and des‐γ‐carboxy prothrombin (DCP) and tumor volume (TV), called ADV score, has been shown to be prognostic of hepatocellular carcinoma (HCC) recurrence following hepatic resection (HR) or liver transplantation.MethodsThis multicenter, multinational validation study included 9200 patients who underwent HR from 2010 to 2017 at 10 Korean and 73 Japanese centers, and were followed up until 2020.ResultsAFP, DCP, and TV showed weak correlations (ρ ≤ .463, r ≤ .189, p < .001). Disease‐free survival (DFS), overall survival (OS), and post‐recurrence survival rates were dependent on 1.0 log and 2.0 log intervals of ADV scores (p < .001). Receiver operating characteristic (ROC) curve analysis showed that ADV score cutoffs of 5.0 log for DFS and OS yielded the areas under the curve ≥ .577, with both being significantly prognostic of tumor recurrence and patient mortality at 3 years. ADV score cutoffs of ADV 4.0 log and 8.0 log, derived through K‐adaptive partitioning method, showed higher prognostic contrasts in DFS and OS. ROC curve analysis showed that an ADV score cutoff of 4.2 log was suggestive of microvascular invasion, with both microvascular invasion and an ADV score cutoff of 4.2 log showing similar DFS rates.ConclusionsThis international validation study demonstrated that ADV score is an integrated surrogate biomarker for post‐resection prognosis of HCC. Prognostic prediction using ADV score can provide reliable information that can assist in planning treatment of patients with different stages of HCC and guide individualized post‐resection follow‐up based on the relative risk of HCC recurrence.

show abstract

Quantitative Prediction of Posttransplant Hepatocellular Carcinoma Prognosis Using ADV Score: Validation with Korea-Nationwide Transplantation Registry Database

Park

Hwang

You

et al. 2023

Journal of Gastrointestinal Surgery

View full text Add to dashboard Cite

Quantitative Prognostic Prediction Using ADV Score for Hepatocellular Carcinoma Following Living Donor Liver Transplantation

Cited by 15 publications

References 25 publications

Selection criteria of living donor liver transplantation for hepatocellular carcinoma developed in Korean transplant centers

Selection criteria of living donor liver transplantation for hepatocellular carcinoma developed in Korean transplant centers

Validation of quantitative prognostic prediction using ADV score for resection of hepatocellular carcinoma: A Korea–Japan collaborative study with 9200 patients

Quantitative Prediction of Posttransplant Hepatocellular Carcinoma Prognosis Using ADV Score: Validation with Korea-Nationwide Transplantation Registry Database

Contact Info

Product

Resources

About